Skip Navigation LinksHome > June 2012 - Volume 112 - Issue 6 > FDA Approves First Drug for Endogenous Cushing's Syndrome
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000415123.61735.8e
Drug Watch

FDA Approves First Drug for Endogenous Cushing's Syndrome

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* Korlym is the first drug approved to help treat endogenous Cushing's syndrome, a rare condition in which the adrenal glands overproduce cortisol. Korlym is a formulation of mifepristone and works by controlling hyperglycemia or type 2 diabetes associated with the disease.

* Korlym's most common adverse effects are nausea, fatigue, headache, arthralgia, vomiting, peripheral edema, dizziness, decreased appetite, and endometrial hypertrophy. Other potentially serious adverse effects include adrenal insufficiency, low potassium levels, vaginal bleeding, and QT interval prolongation.

© 2012 Lippincott Williams & Wilkins, Inc.

Login